Fundz
Real-time · AI · Cross-signal

Genetic Immunity just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Genetic Immunity, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Genetic Immunity and VectorBuilder Form Strategic Partnership for HIV Vaccine Trials

Dec 03, 2024•over 1 year ago

Contract Type

partnership

ChicagoBiotechnologyHealth CareTherapeutics

Description

Genetic Immunity and VectorBuilder have announced a strategic partnership to advance Genetic Immunity's innovative HIV vaccine into a late-stage clinical trial. Under this collaboration, VectorBuilder will provide a Quality by Design (QbD) approach to Process Development, Process Characterization, and GMP Manufacturing services for Genetic Immunity.

Company Information

Company

Genetic Immunity

Location

Chicago, Illinois, United States

About

GI.HU Ltd. is a Hungarian clinical-stage biotechnology company focused on developing plasmid-based DNA therapeutic vaccines for cancer and infectious diseases. Their lead product candidate, DermaVir®, aims to improve the immune response to HIV antigens in HIV-infected individuals, targeting a functional cure. The company is renowned for its innovative approach to vaccine development and has demonstrated promising results in early clinical trials.

Predictive Intelligence
Strategic

ML-powered predictions for Genetic Immunity's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months